{
  "input": {
    "mode": "build_chain",
    "query": {
      "entity": "Gastrointestinal epithelial barrier disorders",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_mesalamine",
          "name": "Mesalamine"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_azathioprine",
          "name": "Azathioprine"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_budesonide",
          "name": "Budesonide"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_certolizumab_pegol",
          "name": "Certolizumab pegol"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_golimumab",
          "name": "Golimumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_vedolizumab",
          "name": "Vedolizumab"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_linaclotide",
          "name": "Linaclotide"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_rifaximin",
          "name": "Rifaximin"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_eluxadoline",
          "name": "Eluxadoline"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 4
    },
    "constraints": {
      "require_disjoint_paths": 2,
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "drug_mesalamine",
          "type": "Drug",
          "label": "Mesalamine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_azathioprine",
          "type": "Drug",
          "label": "Azathioprine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_budesonide",
          "type": "Drug",
          "label": "Budesonide",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_certolizumab_pegol",
          "type": "Drug",
          "label": "Certolizumab pegol",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_golimumab",
          "type": "Drug",
          "label": "Golimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_vedolizumab",
          "type": "Drug",
          "label": "Vedolizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_gastrointestinal_disorder",
          "type": "Disease",
          "label": "Gastrointestinal epithelial barrier disorders",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_TNF_alpha",
          "type": "Target",
          "label": "TNF-alpha",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_mucosal_healing",
          "type": "Phenotype",
          "label": "Mucosal Healing",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_inflammation_management",
          "type": "Phenotype",
          "label": "Inflammation Management",
          "attrs": {
            "agent": "Proponent"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_mesalamine",
          "target": "target_TNF_alpha",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "已知 Mesalamine 对 TNF-alpha 的抑制作用"
        },
        {
          "source": "target_TNF_alpha",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "TNF-alpha 在炎症反应通路中的核心作用"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "disease_gastrointestinal_disorder",
          "relation": "causes",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "炎症通路与胃肠上皮屏障障碍相关"
        },
        {
          "source": "drug_infliximab",
          "target": "target_TNF_alpha",
          "relation": "inhibits",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Infliximab 直接靶向 TNF-alpha"
        },
        {
          "source": "drug_azathioprine",
          "target": "pathway_inflammatory_response",
          "relation": "modulates",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Azathioprine 通过调节免疫通路改善炎症"
        },
        {
          "source": "drug_budesonide",
          "target": "pathway_inflammatory_response",
          "relation": "activates",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Budesonide 通过促进抗炎细胞因子发挥作用"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_TNF_alpha",
          "relation": "inhibits",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Ustekinumab 抑制 TNF-alpha 途径"
        },
        {
          "source": "drug_methotrexate",
          "target": "pathway_inflammatory_response",
          "relation": "inhibits",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Methotrexate 通过抑制细胞增殖改善炎症"
        },
        {
          "source": "drug_golimumab",
          "target": "target_TNF_alpha",
          "relation": "inhibits",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Golimumab 对 TNF-alpha 的特异性抑制"
        },
        {
          "source": "drug_vedolizumab",
          "target": "pathway_inflammatory_response",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Vedolizumab 对肠道局部炎症有针对性作用"
        },
        {
          "source": "target_TNF_alpha",
          "target": "phenotype_mucosal_healing",
          "relation": "supports",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "抑制 TNF-alpha 可促进黏膜愈合"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "phenotype_inflammation_management",
          "relation": "supports",
          "weight": 0.9,
          "agent": "Proponent",
          "rationale": "Inflammatory Response Pathway 相关于炎症管理"
        },
        {
          "source": "drug_azathioprine",
          "target": "phenotype_inflammation_management",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Azathioprine 在炎症管理中的应用"
        }
      ],
      "merge": [],
      "set_weights": []
    },
    "subconclusions": [
      {
        "id": "C1",
        "text": "多种药物通过抑制 TNF-alpha 及调节炎症通路来改善胃肠上皮屏障障碍",
        "confidence": "high"
      },
      {
        "id": "C2",
        "text": "药物对黏膜愈合和炎症管理的影响与其各自的作用靶点相关联",
        "confidence": "medium"
      }
    ],
    "assumptions": [
      "假设药物能够有效到达肠道组织并产生生物活性。"
    ],
    "uncertainties": [
      "各药物的长期安全性与有效性仍需进一步研究。"
    ],
    "next_focus_for_pi": [
      "是否需要评估更多与靶点有关的通路或其他潜在药物？"
    ]
  }
}